Clinical trial
Open Study to Evaluate the Safety of Levocetirizine in Young Children (2 - 6…
NCT00152412 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00152412 |
|---|---|
| Title | Open Study to Evaluate the Safety of Levocetirizine in Young Children (2 - 6 Years) Suffering From Allergic Rhinitis |
| Official title | A 4 Week Open, Multi-center Study Evaluating the Safety of Levocetirizine 1.25 mg b.i.d. Given as 0.5 mg/mL Oral Solution in 2 to 6 Year-old Children Suffering From Allergic Rhinitis. |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Allergic Rhinitis |
| Intervention type | Drug |
| Interventions | Levocetirizine oral solution |
| Enrollment | 30 |
| Start date | Jun 1, 2004 |
| Primary completion | Dec 1, 2004 |
| Completion | Dec 1, 2004 |
| First posted | Sep 9, 2005 |
| Last update posted | Aug 26, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: